CGRP Inhibitors – A Game-Changer for Migraine Prevention and Treatment (Especially in Kids and Teens)
If your child or teen suffers from frequent migraines, you know how disruptive they can be—missed school days, canceled activities, and constant worry. The good news? In 2026, a revolutionary class of medications called CGRP inhibitors is transforming migraine care for both children and adults.
What Are CGRP Inhibitors and How Do They Work? Calcitonin gene-related peptide (CGRP) is a protein that plays a key role in triggering migraine attacks by causing inflammation and widening blood vessels in the brain. CGRP inhibitors block this pathway, preventing migraines before they start (preventive) or stopping them in their tracks (acute treatment). Unlike older preventive drugs (like topiramate or propranolol), these are migraine-specific and generally better tolerated with fewer side effects.
The Main CGRP Treatments Available in 2026
Monoclonal antibodies (injections): Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), and Vyepti (eptinezumab). These are given monthly or quarterly.
Oral gepants: Nurtec ODT (rimegepant) for prevention or acute relief, Ubrelvy (ubrogepant) and Qulipta (atogepant) for acute or preventive use.
Big News for Pediatric Patients In August 2025, the FDA approved Ajovy (fremanezumab) as the first anti-CGRP preventive treatment for episodic migraine in children and adolescents ages 6–17 who weigh at least 45 kg (about 99 lbs). Clinical trials showed it safely reduced monthly migraine days by nearly half in many kids—offering families a long-awaited targeted option with convenient monthly self-injection or in-office administration.
Who Benefits Most? These medications are especially helpful for patients who haven’t responded well to traditional treatments or who experience 4+ migraine days per month. Studies show 40–60% of patients achieve at least a 50% reduction in migraine frequency. Side effects are usually mild (injection-site reactions, constipation, or mild nausea).
The Bottom Line CGRP inhibitors represent the biggest advance in migraine care in decades. As a pediatric neurologist, I’ve seen children regain their childhood—more school days, sports, and family time—thanks to these therapies.
If migraines are affecting your child or family, don’t wait. At our cash-only pediatric neurology practice in Santa Clarita, we provide personalized evaluations and clear pricing without insurance delays or prior-authorization hassles. Schedule a new-patient consult today and take the first step toward fewer migraines.